Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Portola's Heart Bypass Drug Gets Closed Advisory Committee Session

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA's Cardiovascular and Renal Drugs Advisory Committee will discuss Portola Pharmaceuticals' thromboxane receptor antagonist PRT061103, intended to prevent cardiovascular problems in patients who have developed intolerance to aspirin.

You may also be interested in...

Regulatory And Policy News, In Brief

Endo's Advisory Committee Cancelled

Tamper-Resistance Could Allow New Opioid Formulations To Differentiate Themselves

A claim for tamper-resistance rather than broad abuse-deterrence appears to be the immediate path forward for companies seeking to differentiate a new opioid product by its ability to impede recreational use.

Portola/Novartis Plan Phase III Trial For Elinogrel, With Eyes For Plavix Market

Portola's anti-thrombotic vision: Execs discuss possibilities for two partnered, Phase III ready drugs - elinogrel and betrixaban.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts